SecBot SecBot
PRESS-RELEASE ·Filed Mar 19, 2026

ANVS

Annovis Bio Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

Monitor for future data readouts from the ANVS-25002 trial, as enhanced digital biomarker data could strengthen clinical endpoints and support regulatory strategy. No immediate financial impact expected.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.67
T+0 close · Mar 19, 2026 · via day close
Latest settled
−33.33%
T+60 · $1.78
Vs SPY
−47.68%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 19 $2.67entry
  2. T+1 · 8mo ago −2.62%α −0.88% · $2.60
  3. T+5 · 8mo ago −19.48%α −17.26% · $2.15
  4. T+20 · 7mo ago −29.96%α −37.58% · $1.87
  5. T+60 · 5mo ago −33.33%α −47.68% · $1.78
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Annovis Bio has partnered with NeuroRPM to integrate an FDA-cleared AI-powered digital biomarker platform into its ongoing open-label Parkinson’s disease trial (ANVS-25002). The technology enables real-time, passive monitoring of core PD symptoms using wearables, complementing biological biomarker data from skin-based alpha-synuclein testing to enhance trial precision and real-world evidence collection.

Key Facts

  • Annovis Bio partnered with NeuroRPM to use its FDA-cleared AI platform for real-time monitoring of Parkinson’s symptoms (bradykinesia, tremor, dyskinesia) in the ANVS-25002 open-label study.
  • The study is enrolling 500 patients; 90 have been enrolled so far.
  • NeuroRPM’s platform uses wearable sensors for passive, continuous data collection in real-world settings.
  • Annovis is also using a biomarker test for misfolded phosphorylated alpha-synuclein with >90% sensitivity and specificity.
  • Data from both digital and biological biomarkers will be used to assess symptom changes and potential disease modification.

Financial Impact

No financial terms disclosed; likely low-cost operational enhancement

R&D efficiencytrial data quality

Risk Factors

  • Integration challenges with new digital platform may affect data consistency.
  • No guarantee that improved monitoring will translate into positive clinical outcomes or regulatory approval.

Market Snapshot

Exchange
NYSE

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3258883

US Market Status

Market Closed · Opens in 5h 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 19, 2026